MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
363.39
-0.23
-0.06%
Pre Market: 363.50 +0.11 +0.03% 08:14 07/13 EDT
OPEN
363.08
PREV CLOSE
363.62
HIGH
364.90
LOW
361.14
VOLUME
153
TURNOVER
511.89M
52 WEEK HIGH
388.36
52 WEEK LOW
264.02
MARKET CAP
196.12B
P/E (TTM)
25.26
1D
5D
1M
3M
1Y
5Y
1D
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
TipRanks · 13m ago
Amgen price target raised to $312 from $307 at BofA
TipRanks · 1h ago
Amgen price target raised to $343 from $340 at Guggenheim
TipRanks · 1h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Denali Therapeutics (DNLI) and Amgen (AMGN)
TipRanks · 1h ago
Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited
TipRanks · 2h ago
Weekly Report: what happened at AMGN last week (0706-0710)?
Weekly Report · 2h ago
XLV, AMGN, ABT, GILD: ETF Inflow Alert
NASDAQ · 2d ago
Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors
Dow Jones · 3d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.